DanCann Pharma A/S
DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company's development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 Cann… Read more
DanCann Pharma A/S (DCPXF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.302x
Based on the latest financial reports, DanCann Pharma A/S (DCPXF) has a cash flow conversion efficiency ratio of 0.302x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.10 Million) by net assets ($13.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DanCann Pharma A/S - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how DanCann Pharma A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
DanCann Pharma A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DanCann Pharma A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elementos Ltd
AU:ELT
|
-0.021x |
|
AB Science S.A
PINK:ABSCF
|
0.149x |
|
APEX International Financial Engineering Res & Tech Co Ltd
TWO:5210
|
0.016x |
|
Nanexa AB
ST:NANEXA
|
0.175x |
|
Clipper Realty Inc
NYSE:CLPR
|
-0.076x |
|
Black Mammoth Metals Corporation
PINK:LQRCF
|
-0.010x |
|
SBF AG
F:CY1K
|
N/A |
|
Bon Fame Co Ltd
TWO:8433
|
0.021x |
Annual Cash Flow Conversion Efficiency for DanCann Pharma A/S (2019–2024)
The table below shows the annual cash flow conversion efficiency of DanCann Pharma A/S from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $13.57 Million | $-708.00K | -0.052x | +95.88% |
| 2023-09-30 | $9.51 Million | $-12.03 Million | -1.266x | -577.51% |
| 2022-09-30 | $62.79 Million | $-11.73 Million | -0.187x | +16.81% |
| 2021-09-30 | $53.37 Million | $-11.98 Million | -0.225x | -29.91% |
| 2020-09-30 | $44.33 Million | $-7.66 Million | -0.173x | -142.15% |
| 2019-09-30 | $-625.27K | $-256.42K | 0.410x | -- |